Preparing for the digital journeyFresh off his appearance at this year’s Frontiers Health conference, we sat down with Sandoz’s head of digital Share XPreparing for the digital journeyhttps://deep-dive.pharmaphorum.com/magazine/patient-engagement/preparing-for-the-digital-journey-sandoz-patients-andre-heeg/
Chasing Mylan, Hikma tries again with rejected generic Advair in USUK-listed Hikma Pharma has filed a response to the FDA that it hopes will clear the way for Share XChasing Mylan, Hikma tries again with rejected generic Advair in UShttps://pharmaphorum.com/news/chasing-mylan-hikma-tries-again-with-rejected-generic-advair-in-us/
Sandoz buys Aspen’s Japanese generics business for up to $434 millionNovartis’ biosimilars and generics division Sandoz has agreed to buy the Japanese business of the global generics firm Share XSandoz buys Aspen’s Japanese generics business for up to $434 millionhttps://pharmaphorum.com/news/sandoz-buys-aspens-japanese-generics-business-for-up-to-434-million/
FDA finally approves Sandoz’s Neulasta biosimilar, but will Amgen put up a fight?The FDA has approved Sandoz’s pegfilgrastim biosimilar, a cheaper version of Amgen’s long-lasting and big-selling white blood cell Share XFDA finally approves Sandoz’s Neulasta biosimilar, but will Amgen put up a fight?https://pharmaphorum.com/news/fda-finally-approves-sandozs-neulasta-biosimilar-but-will-amgen-put-up-a-fight/
Sandoz says ‘no’ to Pear Therapeutics’ digital apps, handing back rightsNovartis has made no secret of its desire to become a leader in digital therapeutics (DTx), but that Share XSandoz says ‘no’ to Pear Therapeutics’ digital apps, handing back rightshttps://pharmaphorum.com/news/sandoz-says-no-to-pear-therapeutics-digital-app-handing-back-rights/
Novartis strikes marketing deal for Polpharma’s potential Tysabri biosimilarNovartis’ biosimilars and generics arm Sandoz has struck a deal with Polpharma Biologics to market a proposed biosimilar Share XNovartis strikes marketing deal for Polpharma’s potential Tysabri biosimilarhttps://pharmaphorum.com/news/novartis-strikes-marketing-deal-for-polpharmas-potential-tysabri-biosimilar/
Three years after approval, court blocks US launch of Enbrel biosimilarSandoz is to appeal a court decision preventing it from launching a cheaper biosimilar competitor to Amgen’s Enbrel Share XThree years after approval, court blocks US launch of Enbrel biosimilarhttps://pharmaphorum.com/news/three-years-after-approval-court-blocks-us-launch-of-enbrel-biosimilar/
Optimising market access for biosimilarsWe speak to Sandoz’s global head of biopharmaceuticals, Stefan Hendriks, about the remaining challenges in market access for Share XOptimising market access for biosimilarshttps://pharmaphorum.com/views-analysis-market-access/optimising-market-access-for-biosimilars/
Developing with start-up DNAAs head of digital at Sandoz, Andre Heeg is at the forefront of transformation both within his company Share XDeveloping with start-up DNAhttps://deep-dive.pharmaphorum.com/magazine/access-and-commercialisation/sandoz-andre-heeg-digital-startups/
